Figure 5
From: Entinostat as a combinatorial therapeutic for rhabdomyosarcoma
Impact of entinostat in combination with chemotherapies on tumor growth of ARMS PDX model CTG-1916. (A) Tumor growth of vehicle treated mice (n = 4). (B) Tumor growth of 4 mg/kg vinorelbine treated mice (n = 4). (C) Tumor growth of 50 mg/kg cyclophosphamide treated mice (n = 4). (D) Tumor growth of 3 mg/kg doxorubicin treated mice (n = 3). (E) Tumor growth of 0.15 mg/kg topotecan treated mice (n = 4). (F) Tumor growth of 4 mg/kg entinostat treated mice (n = 4). (G) Tumor growth of 4 mg/kg entinostat and 4 mg/kg vinorelbine treated mice (n = 4). (H) Tumor growth of 4 mg/kg entinostat and 50 mg/kg cyclophosphamide treated mice (n = 4). (I) Tumor growth of 4 mg/kg entinostat and 3 mg/kg doxorubicin treated mice (n = 3). (J) Tumor growth of 4 mg/kg entinostat and 0.15 mg/kg topotecan treated mice (n = 4). Each line represents one mouse’s tumor volume over time.
